Can bacteremia due to glycopeptide-susceptible Enterococcus faecium be treated with linezolid?

Linezolid versus glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteremia: A propensity-score matched comparative study.

  • Echeverria-Esnal D. et al.
  • Rédigé par : Dr Philippe Lesprit
Vancomycin is the first-line treatment of glycopeptide (GP)-susceptible E. faecium (GSEF)-bloodstream infections (BSI) except for the rare amoxicillin-sensitive strains. GP have many disadvantages: slow bactericidal activity, toxicity and complex administration procedures requiring plasma concentrations monitoring. Alternatives would therefore be useful and linezolid (LNZ) could be a suitable c...
Ce contenu est à destination des professionnels de santé. Merci de vous identifier.
This content is intended for healthcare professionals. Thank you for identifying yourself.

Déjà inscrit / Already registered ?

Créer un compte / Create an account

Créer un compte ne prend que quelques minutes et vous permettra d'accèder à l'ensemble des contenus du site.
Creating an account takes only instant and will allow you to access all the content of the website.